Abionyx Pharma SA (ABNX) — Cash Flow-to-Debt Ratio
Abionyx Pharma SA (ABNX) has a Cash Flow-to-Debt Ratio of -0.22x as of June 2025, meaning its operating cash flow of €-1.70 Million could theoretically repay 0% of its total liabilities (€7.56 Million) in one year. Check Abionyx Pharma SA cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Abionyx Pharma SA Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Abionyx Pharma SA across 12 annual periods. Also explore Abionyx Pharma SA total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Abionyx Pharma SA (2013–2024)
Year-by-year debt coverage analysis for Abionyx Pharma SA. For market capitalisation and broader financial context, see ABNX stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.60x | €-3.60 Million | €6.03 Million | ▼ -11.7% |
| 2023 | -0.54x | €-3.70 Million | €6.91 Million | ▼ -37.8% |
| 2022 | -0.39x | €-3.36 Million | €8.65 Million | ▲ +35.3% |
| 2021 | -0.60x | €-6.69 Million | €11.15 Million | ▼ -266.5% |
| 2020 | -0.16x | €-599.00K | €3.66 Million | ▲ +85.2% |
| 2019 | -1.10x | €-3.95 Million | €3.58 Million | ▼ -70.8% |
| 2018 | -0.65x | €-6.00 Million | €9.30 Million | ▲ +33.2% |
| 2017 | -0.97x | €-9.09 Million | €9.41 Million | ▲ +27.2% |
| 2016 | -1.33x | €-19.20 Million | €14.46 Million | ▼ -25.0% |
| 2015 | -1.06x | €-13.71 Million | €12.91 Million | ▼ -248.1% |
| 2014 | -0.31x | €-3.30 Million | €10.82 Million | ▲ +83.7% |
| 2013 | -1.87x | €-14.49 Million | €7.76 Million | — |